BMS College of Engineering, Bengaluru

Presentation on BGS (20MBA2PCBGC)

TOPIC: NOVARTIS PATENT CASE

Presented by
Bhoomik Surya - 1BM21BA011
Darshan R - 1BM21BA016
Chandrashekar E - 1BM21BA015
Manoj Kumar S - 1BM21BA045
Nagaraj N - 1BM21BA049
Nataraja T - 1BM21BA051

Submitted to
Prof. Tejaswi Patil
Assistant Professor
Department of Management Studies, BMSCE
 CONTENTS
• Company profile
• Patent
• Product patent and Process patent
• Overview of Novartis
• Issues
• About Glivec
• Pricing
• Why patent got rejected?
• Judgement
• Conclusion

2
 Introduction
Novartis

Industry : Pharmaceutical
Founder : John Rudolf
Alexander Clavel
Founded : 1996
CEO : Vasant Narasimhan (2018)
Headquarters : Basel, Switzerland and
Cambirdge, USA

3
 What is Patent ?
• A patent is a grant from the government
which confers on the guarantee for a
limited period of time the exclusive
privilege of making, selling and using
the invention for which a patent has been
granted.

• THE INDIAN PATENT ACT

Governed by patent act 1970 and rules
1972.

4
Product patent and Process patent

PRODUCT PROCESS
PATENT PATENT

• It is provided to end • It is provided to process

product and not for product

• Validity is 20 years • Validity is 20 years

• Monopoly • They do not enjoy

monopoly

• It provides high range of • It provides low range of

protection protection to the products

5
 Overview of Novartis
➢ New version of cancer drug called Glivec.
➢ The case hinged on sec.3(d) of the Indian Patents Act.
➢ 300,000 people consumed generic drugs of cheap rate.
➢ Whereas 16,000 people use Glivec.

6
 Issues involved
• Whether Glivec is a patentable product?
• Whether it involved Ever-greening?

7
Glivec

8
Pricing

9
 Why patent got rejected?
• In 2006, the Indian Patent Office first refused Glivec's patent
under Section 3(d) of the Indian Patent Act arguing that it was
only a modified version of an existing drug, Imatinib, and
therefore that the drug was not innovative.

10
 Court hearing
• In 2013, supreme court rejected the appeal.
• Reasons behind rejection.

11
 Conclusion

• The judgement of Novartis case can be regarded as the

most fruitful, viable and traceable decision that meet the
human rights to the highest ends.

12
Thank you
Q&A

13